HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zinc Citrate Clinical Data Support Category I Efficacy - Colgate

This article was originally published in The Rose Sheet

Executive Summary

Data from a double-blind, stratified six-month clinical study on the efficacy of zinc citrate in reducing plaque and gingivitis support Category I classification of the ingredient, Colgate-Palmolive states.

You may also be interested in...



Colgate Bids To Expand U.S. Toothpaste Lineup Through FDA Rulemaking

Colgate seeks regulatory approval for a version of its Colgate Sensitive Multi-Protection toothpaste in a formulation it already markets internationally. The request made in a citizen petition comes after Colgate’s plan to expand its U.S. toothpaste business failed when FDA did not give approval for Sensitive Pro-Relief with arginine.

Plaque Draft Needs Further Data On Mouthwash Ingredients - CTFA/NDMA

FDA's Dental Plaque Products Subcommittee draft report recommendations regarding the use of alcohol in mouthwashes need further scientific explanation, NDMA Pharmacology and Toxicology Director Patrice Wright, PhD, stated at the group's final panel meeting held in Rockville, Md. Dec. 2-3.

Zinc Chloride, SLS Dental Rinse Combo Needs More Efficacy Data

The ingredient combination of zinc chloride, sodium citrate, hydrogen peroxide and sodium lauryl sulfate is Category I for safety, but efficacy data for the dental rinse combo are insufficient to determine its effectiveness for antiplaque/antigingivitis claims, FDA's Dental Plaque Subcommittee recommended unanimously at the group's final meeting in Rockville, Md. Dec. 2-3.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008796

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel